Anaprazole

Summary

Anaprazole (CHEMBL4651083) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 8
• Chemistry: 400.5 Da · C21H24N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4651083
Name	Anaprazole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	156009457
Molecular formula	C21H24N2O4S
Molecular weight	400.5
InChIKey	JYSIFLQJDVIWKM-UHFFFAOYSA-N

SMILES: CC1=C(C=CC=C1OCCCOC)CS(=O)C2=NC3=C(N2)C=C4CCOC4=C3

IUPAC name: 2-[[3-(3-methoxypropoxy)-2-methylphenyl]methylsulfinyl]-6,7-dihydro-1H-furo[2,3-f]benzimidazole

Parent form; salt/anhydrous children: CHEMBL4650347

Patent coverage: 4 distinct patent families (5 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	3
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07345689	PHASE4	NOT_YET_RECRUITING	A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations
NCT07010107	PHASE3	RECRUITING	A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.
NCT07606833	PHASE3	NOT_YET_RECRUITING	The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
NCT04215653	PHASE3	UNKNOWN	A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
NCT05604261	PHASE2	UNKNOWN	A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
NCT04463173	PHASE1	COMPLETED	Food Effect Study of Anaprazole in Healthy Chinese Subjects
NCT04466748	PHASE1	COMPLETED	A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
NCT04471922	PHASE1	COMPLETED	A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).